DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib.

Trial Profile

DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms DoviGIST
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 Jul 2014.
    • 27 Dec 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top